MRK-409

MRK-409
Names
IUPAC name
7-Cyclobutyl-3-(2,6-difluorophenyl)-6-[(2-methyl-1,2,4-triazol-3-yl)methoxy]-[1,2,4]triazolo[4,3-b]pyridazine
Other names
  • MK-0343
  • 1,2,4-Triazolo(4,3-b)pyridazine, 7-cyclobutyl-3-(2,6-difluorophenyl)-6-((1-methyl-1H-1,2,4-triazol-5-yl)methoxy)-
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
DrugBank
UNII
  • InChI=1S/C19H17F2N7O/c1-27-16(22-10-23-27)9-29-19-12(11-4-2-5-11)8-15-24-25-18(28(15)26-19)17-13(20)6-3-7-14(17)21/h3,6-8,10-11H,2,4-5,9H2,1H3
    Key: GOIFCXRIFSYPFG-UHFFFAOYSA-N
  • CN1C(=NC=N1)COC2=NN3C(=NN=C3C4=C(C=CC=C4F)F)C=C2C5CCC5
Properties
C19H17F2N7O
Molar mass 397.390 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

MRK-409, also known as MK-0343, is a GABAA receptor partial agonist.

It was designed to be a non-sedative anxiolytic, however its development was halted because it produced sedation in humans.

Pharmacodynamics

Despite lacking the benzodiazepine chemical structure, MRK-409 acts on the benzodiazepine binding site, it is therefore a nonbenzodiazepine.

MRK-409 binds to the α1, α2, α3 and α5 subunits of the GABAA receptor.

In rats, it produces minimal to no sedation, however it produces sedation in humans at doses above 1 mg.

See also